Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375297 · ClinicalTrials.gov registry record · Phase 4
Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women
A Phase 4 study of Depression and Sexual Dysfunction, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00375297 is a Phase 4 study of Depression and Sexual Dysfunction that has completed, run by University of New Mexi. The registered enrollment target is 100 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00375297, a Phase 4 study of Depression and Sexual Dysfunction, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.
Conditions Studied
Interventions
- DRUG sildenafil
Study Locations (1)
New Mexico
- University of New Mexico Health Sciences Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375297
The ClinicalTrials.gov registry entry for NCT00375297 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which sildenafil is the first listed.
NCT00375297 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT00375297 about?
NCT00375297 is a clinical study titled "Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women". This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.
What is the current status of trial NCT00375297?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2001-01. Estimated completion is 2005-06.
What conditions does trial NCT00375297 study?
This clinical trial studies the following conditions: Depression, Sexual Dysfunction.
What interventions are being tested in trial NCT00375297?
The interventions under investigation include: sildenafil (DRUG).
Who is sponsoring clinical trial NCT00375297?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00375297 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.